Search company, investor...
Relievant Medsystems company logo

Relievant Medsystems

relievant.com

Founded Year

2004

Stage

Series G | Alive

Total Raised

$223.6M

Last Raised

$70M | 2 yrs ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+110 points in the past 30 days

About Relievant Medsystems

Relievant provides the underserved population with a low-risk therapy that can eliminate back pain while preserving other therapeutic options. The Company's Intracept System is a minimally invasive procedure that uses radiofrequency energy delivered through a small access tube into the vertebral body to ablate the Basivertebral nerve. The nerve, thought to significantly contribute to chronic low back pain, can no longer generate pain signals following ablation. The company was founded in 2004 and is based in Minneapolis, Minnesota.

Headquarters Location

8500 Normandale Lake Blvd Suite 2150

Minneapolis, Minnesota, 55437,

United States

650-368-1000

Missing: Relievant Medsystems's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

ESPs containing Relievant Medsystems

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Life Sciences / Medical Devices Tech

Bioelectronic neuromodulators alleviate symptoms and treat diseases by targeting and manipulating (with electrical currents) specific electrical circuits in the body. This approach has a broad array of applications — from spinal cord stimulation for pain relief to tibial nerve stimulation for overactive bladders to vagus nerve stimulation for seizure prevention.

Relievant Medsystems named as Highflier among 14 other companies, including Verily Life Sciences, Stimdia Medical, and Cala Health.

Missing: Relievant Medsystems's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Relievant Medsystems

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Relievant Medsystems in 1 CB Insights research brief, most recently on Mar 12, 2020.

Expert Collections containing Relievant Medsystems

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Relievant Medsystems is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

11,883 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,901 items

Relievant Medsystems Patents

Relievant Medsystems has filed 1 patent.

The 3 most popular patent topics include:

  • Bones of the vertebral column
  • Orthopedic surgical procedures
  • Medical equipment
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/5/2018

10/18/2022

Medical equipment, Dosage forms, Orthopedic surgical procedures, Conidae, Skeletal system

Grant

Application Date

10/5/2018

Grant Date

10/18/2022

Title

Related Topics

Medical equipment, Dosage forms, Orthopedic surgical procedures, Conidae, Skeletal system

Status

Grant

Latest Relievant Medsystems News

Relievant Medsystems Announces Updated Policy Statement and Guideline for Basivertebral Nerve Ablation from the International Society for the Advancement of Spine Surgery

Nov 8, 2022

Minneapolis, Minnesota, UNITED STATES MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Relievant Medsystems , a company dedicated to transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP), today announced that the International Society for the Advancement of Spine Surgery (ISASS) has published an updated Policy Statement and Literature Review of Intraosseous Basivertebral Nerve (BVN) ablation in the October issue of the International Journal of Spine Surgery . The ISASS policy recommends intraosseous BVN ablation as the most successful way to address vertebrogenic chronic low back pain. This update follows the September publication of Best Practice Guidelines on the Diagnosis and Treatment of Vertebrogenic Low Back Pain with BVN Ablation from the American Society of Pain and Neuroscience (ASPN) and demonstrates additional society support for BVN ablation. Relievant Medsystems’ minimally invasive Intracept ® Procedure is the only FDA-cleared treatment for chronic vertebrogenic low back pain. “We see the positive impact that the Intracept Procedure has on patients, and expanded society support of BVN ablation further underscores the efficacy of this treatment for chronic vertebrogenic low back pain,” said Tyler Binney, President and CEO of Relievant Medsystems. “These updated guidelines, in addition to our substantial base of clinical evidence, will help to continue driving awareness and adoption of this proven therapy.”   The Intracept Procedure uses targeted radiofrequency energy to stop the BVN from transmitting pain signals to the brain. The procedure is typically performed in an outpatient surgery center and takes approximately one hour. Based on existing data, patients typically experience minimal post-procedure pain and generally quick recovery times. Patients often feel pain relief within two weeks of being treated with the Intracept Procedure. About Vertebrogenic Pain Of the 30 million people in the U.S. with chronic low back pain, 1 in 6 are likely to have vertebrogenic pain, a distinct type of chronic low back pain caused by damage to vertebral endplates, the interface between the disc and the vertebral body. Patients typically have pain in the middle of their low back, which worsens when they bend over, sit for long periods of time, or when they are active. A physician can confirm a patient’s pain is vertebrogenic by observing Modic changes, a biomarker seen on standard MRI that indicates inflammation at the vertebral endplate. About Relievant Medsystems Relievant Medsystems is a commercial-stage medical device company transforming the diagnosis and treatment of vertebrogenic pain, a form of Chronic Low Back Pain (CLBP), with the Intracept Procedure – a novel, clinically proven and commercially available treatment designed to improve the quality of life for millions of indicated patients. For more information about Relievant Medsystems and the Intracept Procedure, visit www.relievant.com . Media Contact:

Relievant Medsystems Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Relievant Medsystems Rank

Relievant Medsystems Frequently Asked Questions (FAQ)

  • When was Relievant Medsystems founded?

    Relievant Medsystems was founded in 2004.

  • Where is Relievant Medsystems's headquarters?

    Relievant Medsystems's headquarters is located at 8500 Normandale Lake Blvd, Minneapolis.

  • What is Relievant Medsystems's latest funding round?

    Relievant Medsystems's latest funding round is Series G.

  • How much did Relievant Medsystems raise?

    Relievant Medsystems raised a total of $223.6M.

  • Who are the investors of Relievant Medsystems?

    Investors of Relievant Medsystems include Canaan Partners, Morgenthaler Ventures, New Enterprise Associates, Endeavour Vision, Lightstone Ventures and 7 more.

  • Who are Relievant Medsystems's competitors?

    Competitors of Relievant Medsystems include Verily Life Sciences, Theranica, Orchestra BioMed, Stimdia Medical, Cala Health, Lungpacer Medical, Saluda Medical, Cardionomic, Rune Labs, BrainQ and 48 more.

Compare Relievant Medsystems to Competitors

SetPoint Medical Logo
SetPoint Medical

SetPoint Medical is developing a bioelectronic medicine platform using a small implanted device that activates the body's natural Inflammatory Reflex and produces a systemic anti-inflammatory effect.

e
eNeura Therapeutics

eNeura Therapeutics develops the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraines.

C
Cala Health

Cala Health develops wearable neuromodulation therapies to deliver individualized peripheral nerve stimulation. It was founded in 2014 and is based in San Mateo, California.

BrainQ Logo
BrainQ

BrainQ is a clinical-stage company developing a therapy for neurological recovery using frequency-tuned electromagnetic fields.

N
Noctrix Health

Noctrix Health is developing therapeutic wearables that empower patients to take control of their chronic medical conditions.

Neuros Medical Logo
Neuros Medical

Neuros Medical focuses on the development of proprietary therapies for unmet needs to patients worldwide. The company’s patented platform technology, Electrical Nerve Block, focuses on the treatment of chronic pain in a variety of applications including post-amputation pain, chronic post surgical pain, and chronic migraine.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.